Introduction {#S1}
============

The incidence of primary brain tumors in the United States is approximately 30 per 100,000 persons; one third of these tumors are malignant. The overall 5-year survival for malignant primary brain tumors is 30% and can be as low as ∼5% in the most common aggressive subtype, glioblastoma (GBM) ([@B58]). In children, primary brain and spinal cord tumors are the most common childhood solid tumor malignancy and the most common cause of cancer related death in children under 15 years ([@B70]; [@B83]). The diagnosis of primary brain tumors has become increasingly dependent upon molecular tumor profiling, with a number of tumors now defined by key molecular alterations ([@B40]). Many molecular biomarkers are already being used in clinical practice for prognosis and to guide targeted therapy ([@B77]). This number will only increase with the development of more targeted therapies. Tumors that have metastasized to the brain are often resistant to treatment and have a low 5-year survival rate (2.4% across all tumor types) ([@B25]; [@B7]; [@B59]; [@B66]).

Current techniques for molecular profiling of brain tumors primarily rely on tissue obtained through small biopsies or surgical resection. Brain biopsy is an invasive procedure, which carries a risk of mortality reported to be between 2.8 and 12% depending on technique and patient population ([@B84]; [@B42]). Moreover, tumors in certain anatomic locations such as the brain stem are dangerous to biopsy or resect ([@B35]; [@B42]).

Liquid biopsy techniques are fast emerging as non-invasive methods for tumor diagnosis and molecular characterization. Cell-free DNA (cfDNA) refers to DNA that has entered the circulation after cell death. In healthy patients, the majority of this DNA comes from the apoptosis of hematopoietic cells and has a length of ∼167 base pairs. The total amount of circulating cfDNA is increased in patients with solid tumors ([@B37]), and the tumor-derived cfDNA is also shorter in length (∼145 bp) ([@B50]; [@B85]). cfDNA is also present in other body fluids such as sputum, stool, saliva, urine, pleural fluid, and cerebrospinal fluid (CSF) ([@B63]). CSF is an appealing source for liquid biopsy of CNS tumors as it may be obtained through the minimally invasive procedure of diagnostic lumbar puncture, which is performed routinely for many neurologic diseases with a very low serious complication rate ([@B16]). Diagnostic lumbar puncture is clinically indicated for CNS tumor staging to evaluate CSF cytology in some tumors such as medulloblastoma with a known rate of metastatic CSF dissemination ([@B32]). This review will discuss the use of cell-free DNA in brain and spinal cord tumor diagnosis and characterization and the advantages of using CSF as the sample of choice. Preanalytical variables and detection strategies are also covered.

cfDNA From CSF Is More Sensitive Than Plasma in Diagnosing Brain Neoplasia {#S2}
==========================================================================

Circulating tumor-derived cell-free DNA has emerged as a non-invasive modality for genetic characterization of many solid tumors. Advantages of using cell free DNA include that it is present in the plasma of most patients and that it allows serial monitoring of tumor burden and response to therapy. In a study of 640 patients, tumor-derived cfDNA was detected in the blood of \>75% of patients with many types of advanced carcinomas (stage III/IV as indicated in the paper) and in approximately 50--75% of patients with localized carcinomas. In contrast, it was detected in only 40% of medulloblastoma patients and in \<10% of patients with gliomas. Moreover, the absolute concentration of tumor-derived cfDNA in glioma and medulloblastoma patients was several logs lower than in patients with other tumor types ([@B4]). cfDNA detection has been reported to be more likely in the plasma of patients with large and/or contrast enhancing tumors ([@B5]). A subsequent study of 35 patients, all with primary CNS neoplasia, found that tumor-derived cfDNA could be detected in the CSF of nearly 75% of patients, including all high-grade tumors that were in direct contact with the CSF space ([@B80]). Another study of 10 patients (7 with solid brain tumors and 3 with leptomeningeal metastases) reported that the median concentration of total cfDNA was lower in CSF than in plasma. However, in the absence of widely disseminated disease, mutant allele frequencies were significantly higher in the CSF ([@B61]). This observation was also reported in an additional study of 12 patients (4 with glioblastoma, 6 with metastatic breast carcinoma, and 2 with metastatic lung carcinoma) ([@B14]).

Csf-Derived cfDNA Offers Additional Genetic Information Beyond Tissue Biopsy {#S3}
============================================================================

Genetic analysis of small biopsy specimens may not reflect intratumor heterogeneity or uncover mutations only present at a specific metastatic site ([@B22]). Intratumoral heterogeneity is defined by the presence of different mutations in different parts of the same tumor and is a well-known feature of high-grade glioma ([@B74]; [@B3]; [@B41]) and medulloblastoma ([@B48]). A study of 10 patients with newly diagnosed glioblastoma whose tumors were sequenced in different sectors demonstrated that 51% of mutations were clonal (present in all tumor cells), 3% were subclonal (present in a subset of tumor cells) but shared between different sectors, and that 46% of mutations were subclonal and unique to a particular sector. Moreover, 80% of patients had potentially targetable mutations that were not shared between sectors, which highlights the danger of relying on single-sector sequencing information ([@B41]).

Using CSF-derived cell free DNA may overcome the under-sampling bias that may occur with small tissue biopsies. In patients with CNS restricted disease (primary or metastatic), mutations have been found in CSF or plasma cfDNA that are not present in the corresponding biopsy specimen ([@B14]; [@B61]; [@B49]). In the context of disseminated disease, mutations in CSF cfDNA recapitulate brain and meningeal metastasis that are not found in plasma cfDNA or extracranial metastases ([@B14]).

###### 

Comparison of technology platforms for detection of cell-free DNA.

  ***Method***                     ***Analytical sensitivity***   ***Mutations***                         ***Targets per assay***   ***Mutation info required?***   ***Turnaround time***                ***Cost***
  -------------------------------- ------------------------------ --------------------------------------- ------------------------- ------------------------------- ------------------------------------ ------------
  **PCR-Based**                                                                                                                                                                                          
  Digital PCR^a^                   0.01--0.1%                     SNV, indels, CNV, structural            1--4                      Yes                             Fast                                 \$
  BEAMing^b^                       0.01%                          SNVs, indels                            1--20                     Yes                             Fast                                 \$
  **Next generation sequencing**                                                                                                                                                                         
  **Targeted panels**                                                                                                                                                                                    
  Deep sequencing^c^               0.05--0.1%                     SNV, indels                             Panel                     No                              Intermediate                         \$\$\$
  Error corrected NGS^d^           \<0.02%                        SNV, indels                             Panel                     No                              Intermediate                         \$\$\$
  TAm-Seq^e^                       \<0.1%                         SNV, indels                             Panel                     No                              Intermediate                         \$\$\$
  CAPP-Seq^f^                      \<0.02%                        SNV, indels, structural, CNV            Panel                     No                              Intermediate                         \$\$\$
  cSMART^g^                        0.01%                          SNV, indels, structural                 Panel                     No                              Intermediate                         \$\$\$
  **Whole genome/exome**                                                                                                                                                                                 
  Traditional^h^                   5 -- 10%                       SNV, indels, structural variants, CNV   Genome                    No                              Intermediate (analysis is complex)   \$\$\$\$
  Low-Pass^i^                                                     Structural variants, CNV                Genome                    No                              Fast                                 \$\$
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Clinical Applications {#S4}
=====================

Glioma Classification {#S4.SS1}
---------------------

Gliomas are the most common primary brain tumor and are clinically characterized by several key molecular markers in addition to histology and grade. The histologic diagnoses within glioma, including astrocytoma, glioblastoma, and oligodendroglioma, are each further characterized by *IDH* mutation status. Oligodendroglioma is identified by 1p/19q co-deletion, and both astrocytoma and oligodendroglioma are further described as histologic grade II or III, while glioblastoma is by definition grade IV ([@B40]). Methylation status of *MGMT* is another key prognostic marker in glioblastoma, with methylated tumors conferring sensitivity to therapy with temozolomide ([@B27]). Genomic analyses have demonstrated multiple abnormalities such as activating kinase mutations in *EGFR* and *PDGFRA* in malignant glioma, but the success of targeted therapy has been limited to date, which may be at least in part due to tumor heterogeneity ([@B62]). Diffuse midline glioma, H3K27M-mutant is a newly described entity that occurs mainly in the pediatric age range ([@B75]). This tumor is defined by the pathognomonic H3K27M mutation in the *H3F3A* or, less commonly, *HIST1H3B* genes, and all glial tumors with H3K27M are considered grade IV regardless of histologic appearance. In the pediatric age range, low-grade gliomas are more common than high-grade. Pilocytic astrocytoma, a grade I tumor commonly harboring abnormalities of *BRAF*, *FGFR*, or *NF1*, is the most common pediatric brain tumor, and new targeted therapies are expanding therapeutic options ([@B57]). An integrated histologic and molecular diagnosis is strongly prognostic in glioma, with survival ranges between 1 and 15 years ([@B40]). While surgery continues to be an essential component of initial diagnosis and treatment when feasible, monitoring for tumor recurrence is currently by MRI, which is not sensitive for microscopic disease ([@B2]). A panel of seven genes (*IDH1*, *IDH2*, *TP53*, *TERT*, *ATRX*, *H3F3A*, and *HIST1H3B*) has been developed that can accurately classify nearly 80% of malignant gliomas based on genetics alone. A retrospective study of 20 glioma patients demonstrated that this combined digital PCR and targeted sequencing panel could use CSF cfDNA to correctly classify gliomas in 85% of cases and only failed with low grade tumors or those not in direct contact with the ventricles ([@B43]).

Brainstem Tumors {#S4.SS2}
----------------

Many tumors of the brain stem have characteristic alterations ([@B18]; [@B36]). Perhaps the most successful use for CSF cfDNA has been in the characterization of brain stem tumors, which are inherently difficult and dangerous to biopsy. In a study of 57 patients, a next-generation sequencing (NGS) panel of 68 genes commonly mutated in brain stem tumors detected tumor specific mutations in the CSF cfDNA of 82.5% of patients. Consistent with molecular findings from tumor-based studies, two markers in this panel were shown to correlate with overall survival (OS) in patients with diffuse midline glioma in this cohort --- the presence of an *H3F3A/HIST1H3B* mutation was predictive of poor overall survival consistent with the specific entity of H3K27M-mutant diffuse midline glioma, where as an *IDH1* mutation predicted better OS ([@B60]). Targeted therapies for these alterations are currently undergoing clinical trials ([@B39]). *Histone 3* allele-specific PCR and single gene Sanger sequencing assays have been developed to aid the diagnosis of H3K27M-mutant diffuse midline gliomas, with 87.5% clinical sensitivity for CSF cfDNA when compared to tissue testing ([@B9]).

Monitoring Response to Therapy {#S4.SS3}
------------------------------

Brain tumor patients are usually biopsied once during the course of their illness. In patients with primary brain tumors or CNS metastases, mutant allele frequencies have been shown to decrease with surgical and systemic therapy and correlate with tumor burden ([@B14]). Therefore, there is potential that CSF cfDNA could serve as a useful biomarker for monitoring tumor progression and response to therapy ([@B47]). Moreover, genomic alterations that drive the growth of glioma recurrence are distinct from those present in the initial resection, likely due to tumor evolution ([@B31]). Monitoring patients with CSF cfDNA may therefore provide opportunity to provide targeted therapy to tumor recurrences.

cfDNA may prove especially useful in monitoring high-grade gliomas, which present a unique diagnostic challenge. Pseudoprogression of brain tumors is defined by radiographic alterations that are due to treatment rather than tumor growth, including increased lesion size, contrast enhancement, and/or edema, in the absence of increased tumor activity. With the advent of immunotherapy, disease monitoring by imaging alone has become increasingly complicated as the tempo and MRI appearance of tumor progression and response can be less predictable with the use of immunotherapy than traditional cytotoxic therapy ([@B2]). Although pseudoprogression often resolves on its own, in some cases it progresses to treatment-related necrosis ([@B6]; [@B82]). Definitive diagnosis requires a tissue biopsy, which may be difficult to interpret in the setting of extensive necrosis and therapy-related cytologic atypia ([@B65]).

CNS Lymphoma {#S4.SS4}
------------

Primary CNS lymphoma (PCNSL) is part of the differential diagnosis for many space occupying brain lesions ([@B72]), and in contrast to solid primary CNS solid tumors, surgical management is not routinely part of treatment ([@B78]). In a small study of patients with PCNSL, *MYD88* L265P mutations were detected by droplet digital PCR in plasma cfDNA in 8 of 14 patients known to harbor this mutation in their tumors ([@B26]). A similar study of PCNSL patients using a targeted NGS panel detected patient specific mutations in the plasma cfDNA in only 32% of patients, including *MYD88* mutations in 8 of 20 cases ([@B19]). CSF cytology and immunophenotyping by flow cytometry are currently used as alternatives to stereotactic biopsy in patients with suspected PCNSL. Using CSF as a source for cfDNA shows increased clinical sensitivity relative to plasma cfDNA testing (86%), and *MYD88* L265P mutations may be detected even in the absence of positive cytology or flow cytometry ([@B68]). *MYD88* L265P mutations are specific to PCNSL and have not been reported in other brain tumors such as GBM ([@B51]; [@B19]), making this a particularly appealing biomarker. In the future, it may be possible to render the diagnosis of PCNSL based on a *MYD88* L265P molecular result even in the absence of positive cytology.

Brain and Leptomeningeal Metastasis {#S4.SS5}
-----------------------------------

Brain and leptomeningeal metastases are common in certain cancers and carry a very poor prognosis. They are difficult to biopsy and often resistant to treatment. In a study of lung adenocarcinoma patients with leptomeningeal metastasis and known *EGFR* mutations in the primary tumor, patient-specific EGFR mutations were detected in the CSF cfDNA of all 26 patients. Using CSF cfDNA had greater clinical sensitivity than plasma cfDNA or DNA derived from direct cellular lysis of the CSF (86.4 and 73.1%, respectively). Furthermore, the average mutant allele frequencies were highest in CSF-derived cfDNA (62%, vs. 13.9% for direct lysis and 3.5% for plasma), making it more likely that mutations were accurately detected. Many copy number variants were detectable only in the CSF cfDNA and were more abundant in patients who failed tyrosine kinase inhibitor therapy. Common molecular copy number alterations were present in *MET*, *KRAS*, *ERBB2*, *BRAF*, and *ALK*. *EGFR* T790M was identified in the CSF of 30.4% of patients with progression on tyrosine kinase inhibitor treatment vs. 21.7% in plasma ([@B38]). An additional study of 29 lung cancer patients with leptomeningeal metastases revealed CNS-limited single nucleotide variants (SNVs) in *ALK* and *KRAS* ([@B21]). Similar CNS-limited drug resistance mutations have been described in the setting of melanoma and breast carcinoma ([@B64]).

Current definitive diagnosis of leptomeningeal metastasis depends upon CSF cytology, which can be falsely negative in up to 20% of cases with positive clinical and radiographic findings ([@B23]; [@B11]). Tumor-derived cfDNA has been reported to be present in the CSF of breast ([@B13]) and lung carcinoma patients ([@B76]) even in the absence of cytologically malignant cells. One group has shown that the Cobas^®^ (Roche) EGFR Mutation Test v2, an approved companion diagnostic for osimertinib, can detect EGFR mutations, including T790M, from the supernatant cfDNA from CSF cytology samples with 87.5% clinical sensitivity and 100% specificity ([@B34]).

Preanalytical Variables {#S4.SS6}
-----------------------

All laboratory testing consists of pre-analytic, analytic, and post-analytic phases. Pre-analytical variables refer to those that occur prior to testing and include physiologic factors intrinsic to the patient and factors that affect specimen integrity such collection, processing, and storage ([@B12]; [@B53]). Physiologic factors include those that limit the amount of tumor-derived cfDNA present in the CSF. Multiple studies have shown that low grade tumors or those not directly communicating with the CSF space have low to undetectable tumor-derived cfDNA in the CSF ([@B80]; [@B33]; [@B43]; [@B60]). Likewise, detection of tumor-derived cfDNA is less likely in patients with new onset disease ([@B60]). Studies of CSF cytology have shown that obtaining CSF as close to the tumor as possible minimizes the risks of false negative results ([@B8]), though the effect on cfDNA yield has yet to be determined.

Analytical success is dependent upon maintaining cfDNA integrity and minimizing contamination from cellular genomic DNA. However, rigorous studies of these factors in CSF are lacking. In contrast, pre-analytic variables that affect the detection of plasma cfDNA have been investigated. At present, the best practices for handling CSF cfDNA must be inferred from studies of plasma. In standard K~2~EDTA blood collection tubes, it has been shown that separating plasma from cellular components (through centrifugation or filtration) should be performed as soon as possible after collection, ideally within 6 h, to prevent dilution with leukocyte DNA ([@B46]). While we recommend expedient processing of CSF, this factor may not be as important in CSF as this fluid is intrinsically paucicellular. Special cell-stabilizing blood collection tubes have been used to minimize genomic DNA contamination, which allows processing to be delayed for multiple days ([@B56]; [@B15]; [@B46]). Although some labs are using these for CSF ([@B29]), the practice is not standard, and the value of cell-stabilizing tubes has not been systematically investigated. As with plasma, CSF specimens can be stored frozen after processing, but multiple freeze-thaw cycles should be avoided ([@B46]).

Multiple methods for purifying cell free DNA exist, but none of these have been systematically studied in CSF. For example, [@B29] reported that in their general experience, the QIAamp Circulating Nucleic Acid Kit provided better results with CSF. Likewise, [@B30] reported that centrifugation for 10 min at 1000 × *g* is optimal for selection of DNA fragments of ∼150 bp, but others have not confirmed this.

Analytical Strategies: Targeted vs. Broad Approaches {#S4.SS7}
----------------------------------------------------

Methods for analyzing cfDNA can be divided into two broad categories --- targeted approaches for interrogating a single or few variants and broad approaches that cover a panel of genes up to an entire genome. Targeted assays typically use PCR-based techniques, or in rare cases, single gene sequencing. These assays are inexpensive, have a fast turn-around time, and are easy to interpret. Multiple qPCR and modified PCR assays are available, including BEAMing ([@B17]) and the companion diagnostics Therascreen (Qiagen) and Cobas (Roche) ([@B67]), which have an analytical sensitivity of 0.01 to 0.1%. Digital PCR methods allow for quantification of tumor-derived cfDNA levels and can be used to detect copy number variations ([@B44]; [@B81]). These methods usually require prior knowledge of patient specific mutations present in previous biopsies and can be used to monitor disease progression or response to treatment. They can also be used to answer specific directed questions. For example, this approach can be used when knowing the presence or absence of a single genetic change will provide a diagnosis (see the discussion above of PCNSL and brainstem tumors), direct targeted therapy, i.e., *MEK* inhibitors in *BRAF* V600E mutated CNS melanoma ([@B45]), or provide prognostic information, i.e., *TERT* promoter variants in malignant gliomas ([@B69]). Multiple PCR assays can be combined into small panels with relatively fast turn-around time, but analytical sensitivity may be impacted (see discussion above on glioma classification).

Early studies of the analytic validity of CSF-derived cfDNA relied on these targeted methods and compared the presence of known patient specific mutations in paired tissue biopsies and CSF specimens. In clinical practice, this approach is not always feasible, particularly in cases where CSF-derived cfDNA is needed for primary diagnosis. Moreover, targeted approaches will not provide information about tumor heterogeneity or CNS-specific mutations. Targeted massively parallel NGS approaches use PCR amplification or hybrid capture enrichment to focus on a particular subset of the genome and do not rely upon *a priori* knowledge of tumor alterations. However, these assays are more complicated, expensive, and increase turn-around time. In general, analytical sensitivity decreases as the number of targets increases and is optimal with targets totaling less than 200 kilobases ([@B55]). The most sensitive NGS assays (\<0.02%) employ molecular barcoding and error correction and surpass the most sensitive PCR-based assays ([@B52]; [@B55]). This degree of analytical sensitivity may not be universally required for CSF cfDNA; however, molecular barcoding is beneficial in the context of limited DNA input, commonly encountered in the CSF, and in clinical settings of coincident inflammation and/or infection.

Both general cancer gene panels and brain tumor-specific panels have been used to analyze CSF cfDNA. Using an NGS panel of all exons in 341 cancer associated genes with actionable mutations (MSK-IMPACT), alterations were detected in 63% of patients with CNS metastases and 50% of patients with primary brain tumors ([@B64]). The published limit of detection for this panel is between 2--5% for low frequency variants ([@B10]). In a more limited panel of all exons of 67 brain-tumor associated genes and the *TERT* promoter, alterations were detected in 82.5% of patients with brainstem tumors with an analytical sensitivity of 0.15% ([@B60]). A study looking at *EGFR* mutations in the CSF of lung cancer patients with CNS metastases showed that sequencing hotspots was more sensitive than sequencing all *EGFR* exons ([@B21]).

Non-targeted whole genome or exome sequencing has an analytical sensitivity of approximately 5% ([@B28]; [@B1]). At first glance, this broad approach seems appealing in the context of tumors which are inaccessible to biopsy for which we do not have *a priori* knowledge of patient-specific genetic changes. However, in a small study of patients with brain tumors in dangerous anatomic locations, known mutations could not be found in two of four subjects, both of which had variant allele frequencies below 1% ([@B80]). While traditional whole genome sequencing is not feasible in the context of limited cfDNA input, low-pass or shallow whole genome sequencing (∼0.1× coverage) can be used to detect amplifications and deletions ([@B21]). In a study of 13 patients with GBM, shallow whole-genome sequencing was able to detect copy number variants (CNVs) in the CSF cfDNA of 38% of patients ([@B49]).

Conclusion and Future Directions {#S5}
================================

Cell-free DNA has emerged as a powerful biomarker for the diagnosis and characterization of tumors of the central nervous system. Using CSF as a source has several advantages over plasma, including increased clinical sensitivity and the ability to detect CNS-limited mutations. Moreover, cfDNA from CSF is more likely to represent tumor heterogeneity than tissue biopsy, and if sampled over time, allows for the ability to monitor tumor progression and detect tumor evolution and drug resistance mutations.

Most current studies of CSF cfDNA are small and retrospective. A few case reports have demonstrated that CSF cfDNA has been used clinically to guide ([@B45]; [@B24]) and monitor response to therapy ([@B71]). Prospective trials, however, are lacking. Pre-analytical variables need to be systematically studied and optimized. Since absolute quantities of cell-free DNA in the CSF are low, NGS panels need to be strategically designed to be broad enough to cover common mutations while narrow enough to maintain adequate analytical sensitivity.

It has recently been shown that the variation of nucleosome positioning between tissue types can be exploited in cell-free DNA to predict tissue of origin. Notably, this observation extends to malignant tissue, which could be leveraged to facilitate determination of tumor origin from cell-free DNA ([@B73]). This may prove to be a powerful tool in the CSF as it would allow clinicians to determine tumor type in the absence of sequence information and potentially enable disease monitoring. Whether cell-free DNA in the CSF provides a complementary alternative to tissue biopsies in the near future remains an area of active investigation. However, the significant advantages of this analyte for CNS tumors and the rapidly expanding genomic toolbox make this a promising area for additional studies.
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